During pregnancy, the semi-allogeneic fetus needs to avoid maternal immune responses. A specific immune suppression system employing the non-classical MHC class I molecule (MHCI), HLA-G [@b1], [@b2] has been adapted for this purpose. The gene encoding HLA-G is located within the MHC region; however, HLA-G has very low polymorphism by contrast with the high polymorphism of classical MHCI. Although HLA-G is expressed by placental trophoblast cells, these cells do not express major classical MHCI, HLA-A or -B, resulting in the inability to induce immune responses. Cell surface-expressed trophoblast HLA-G can suppress immune responses by binding to inhibitory receptors. The HLA-G receptors reported to date are the leukocyte Ig-like receptors (LILR) B1 and B2, killer cell Ig-like receptor (KIR) 2DL4, CD160 and CD8 [@b2]--[@b4] (Fig. [1](#fig01){ref-type="fig"}). Previous reports clearly demonstrate that LILRB1 and LILRB2 preferentially bind to HLA-G compared with other classical MHCI [@b5]. Intriguingly, HLA-G is expressed in several unusual forms in addition to the conventional heterotrimer, associated with β2m and peptide, made by all classical MHCI. These include: (i) a disulfide-linked β2m-associated dimer; (ii) a β2m-free heavy chain, (iii) its disulfide-linked dimer, and (iv) domain-deleted and soluble splice variants [@b6]. Previous *in vitro* studies using either recombinant proteins, transfectants or cell lines demonstrated that HLA-G can exist as a disulfide-linked dimer of the conventional β2m-associated form (and in some cases, trimeric and oligomeric forms) [@b7], [@b8]. In this issue, Apps *et al*. [@b9] demonstrate that significant amounts of the β2m-associated HLA-G dimer are expressed at the cell surface of normal first trimester trophoblast cells. Furthermore, they also found that LILRB1 is the principal ligand for the HLA-G dimer. These results are consistent with previous studies showing that the HLA-G dimers bind with greater avidity to LILRB1/2 and signal more strongly through LILR than monomeric HLA-G and other classical MHCI [@b10], [@b11] (Fig. [1](#fig01){ref-type="fig"}). Therefore, the HLA-G dimer presumably has a significantly pivotal *in vivo* role in maternal-fetal interface, in comparison with the monomeric form. In addition to the crystal structure of the HLA-G monomer [@b12], the recent structural study [@b10] showed that the disulfide-linked dimer exhibits an oblique configuration exposing two upward facing LILR/CD8 binding sites, readily accessible to receptors, explaining the increased avidity. On the other hand, the peptide-binding grooves are very close, possibly preventing T cell receptor binding (Fig. [1](#fig01){ref-type="fig"}).

![Receptor recognition of the different forms of HLA-G at the maternal-fetal interface. HLA-G can be expressed in various forms in placenta. The structures of β2m-associated HLA-G monomer and dimer are shown. LILRB1 (light blue), which is expressed on decidual antigen-presenting cells (APC) and subsets of NK and T cells, binds to only β2m-associated forms of HLA-G monomer and dimer. LILRB2 (dark blue), whose expression is restricted to decidual APC, binds to both β2m-associated and -free forms of HLA-G monomer and dimer. LILRB1 and LILRB2 presumably bind to HLA-G dimer more strongly than its monomer. The thickness of the arrows corresponds to the signal strength. Both membrane-bound and soluble forms likely inhibit the immune responses of LILRB-expressing cells. On the other hand, the HLA-G recognition of CD160 and KIR2DL4 still remains unclear.](eji0037-1727-f1){#fig01}

There are some reports demonstrating the existence of a β2m-free heavy chain form of HLA-G. Gonen-Gross *et al*. [@b11] demonstrated placental expression of the β2m-free form of HLA-G by *in situ* immunostaining. Furthermore, Morales *et al*. [@b13] recently showed that villous cytotrophoblast cells (vCTB) express the dimeric form of β2m-free HLA-G. Based on these results, Hunt *et al*. [@b14] summarized the expression pattern of HLA-G variants in placenta. These results are different from those of Apps *et al*. [@b9] with regards to the β2m association of HLA-G dimer in placenta, and might be a consequence of the different cell populations used in each study. Recent reports [@b11], [@b15] have shown that LILRB2 can recognize the β2m-free MHCI, but LILRB1 cannot (Fig. [1](#fig01){ref-type="fig"}). Therefore, β2m-free HLA-G confers an inhibitory effect selectively on LILRB2-expressing cells, such as antigen-presenting cells (APC). Furthermore, Kollnberger *et al*. [@b16] showed that β2m-free HLA-B27 dimer binds to KIR3DL2 and KIR3DL1 as well as LILRB2. Thus, it will be of great interest to see whether β2m-free HLA-G dimer binds to LILRB and KIR with greater avidity than monomer.

Emerging studies have revealed the potential roles of various forms of MHCI, including β2m-free MHCI (and its homodimer) and associated forms with other unrelated molecules [@b17]. As described above, HLA-G can exist in similar forms, but possesses unique cysteine residues distinct from other MHCI, including Cys42, which is involved in disulfide-linked dimer formation without any conformational changes. Therefore, both β2m-associated and -free forms of the HLA-G dimer could have distinct roles in immune suppression from those of normal MHCI.

The soluble form of HLA-G (sHLA-G) is secreted and/or shed from the cell surface toward the decidua area. sHLA-G can inhibit immune responses of LILRB1/2-expressing cells in the decidua and can also interact with CD160 expressed on the surface of endothelial cells [@b18], possibly resulting in the anti-angiogenic effects on uterine vascular remodeling in pregnancy. By contrast, sHLA-G binds to KIR2DL4 at the cell surface and is internalized into endosomes, whereas the membrane-bound form of HLA-G cannot, thus stimulating pro-inflammatory and pro-angiogenic cytokines production, which would be helpful in increasing blood supply to the placenta [@b19]. Using a killing assay, Yan *et al*. [@b20] revealed that the KIR2DL4 binding site is located in the C-terminal peptide-binding site of the HLA-G α1 helix. This suggests that the HLA-G dimer may not be able to bind to KIR2DL4 because of the close proximity of the peptide-binding grooves. However, without further biochemical evidence it is not possible to draw any definitive conclusions. Further in-depth investigations, especially comprehensive binding studies with recombinant proteins, will clarify the precise role of HLA-G monomer and dimer interactions with KIR2DL4 and CD160 in immune regulation.

Taken together, the current evidence and the results from Apps *et al.* [@b9] strongly suggest that LILR recognition of HLA-G dimers has a pivotal role to play in immune suppression at the maternal-fetal interface, possibly contributing to the prevention of pregnancy complications such as pre-eclampsia and recurrent abortion. Further detailed analysis of the interaction of HLA-G with LILR and KIR families, CD160 and maybe as yet-unidentified receptors will provide a clear molecular basis of how these interactions may be involved in immune suppression and the control of angiogenesis *in vivo*. These studies may also provide future avenues of research with potential clinical applications.
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